Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 3Active not recruiting 2

Sponsor Class

NIH 6INDUSTRY 5OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Non-Muscle Invasive Bladder Neoplasms 3Urothelial Cancer 1Urinary Bladder Neoplasms 1Acrocephalosyndactylia 1

Interventions

pembrolizumab 131Carboplatin 106Paclitaxel 66Cisplatin 61Gemcitabine 57Pemetrexed 56Bevacizumab 50Docetaxel 47Fluorouracil 40Oxaliplatin 38Dexamethasone 34130-nm albumin-bound paclitaxel 34Leucovorin 33atezolizumab 32Cetuximab 32durvalumab 30Nivolumab 28Rituximab 26Cyclophosphamide 26Capecitabine 26Prednisone 25Fulvestrant 24enzalutamide 23Lenalidomide 22venetoclax 21Letrozole 20Irinotecan 20Doxorubicin 17ribociclib 16pomalidomide 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × erdafitinib × 30 days × Clear all
NCT02365597 2026-06-05

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Janssen Research & Development, LLC

Phase 2 Active not recruiting
239 enrolled 32 charts 1 FDA
Genitourinary

Urothelial Cancer

NCT05316155 2026-06-05

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Janssen Research & Development, LLC

Phase 1/2 Recruiting
235 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05567185 2026-06-05

TAR-210

Janssen Pharmaceutical K.K.

Phase 1 Active not recruiting
5 enrolled
Genitourinary

Acrocephalosyndactylia, Urinary Bladder Neoplasms

NCT06319820 2026-06-05

MoonRISe-1

Janssen Research & Development, LLC

Phase 3 Recruiting
641 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06919965 2026-06-05

MoonRISe-3

Janssen Research & Development, LLC

Phase 3 Recruiting
220 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡